The present invention relates to an industrially feasible and economically viable process for the preparation of fluvoxamine maleate of formula I. ##STR00001##

The present invention relates to an industrially feasible and economically viable process for the preparation of fluvoxamine maleate of formula I. ##STR00001##

Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

Compositions and methods for treating thrombosis, inflammation, and atherosclerosis by administration of a compound that binds to KRIT1 to inhibit binding with HEG1.

Novel Styryl Carboxylate derivatives are provided which exhibit activity for the treatment of immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, neurological diseases, and diabetes.

Disclosed are reagent compositions for metal solvent extraction and methods of preparation and use thereof. In certain embodiments, the disclosure relates to recovering metal values from an aqueous process stream using solvent extraction and employing a mixture of oxime reagents that synergistically improves metal recovery, rate of degradation and/or metal selectivity.

Disclosed are reagent compositions for metal solvent extraction and methods of preparation and use thereof. In certain embodiments, the disclosure relates to recovering metal values from an aqueous process stream using solvent extraction and employing a mixture of oxime reagents that synergistically improves metal recovery, rate of degradation and/or metal selectivity.

The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.

##STR00001##

The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.

##STR00001##

The present disclosure relates to a process for the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile, to use of a compound which is 2-methoxy-5-(4-methylbenzyl)phenol, (3-hydroxy-4-methoxyphenyl)(p-tolyl)methanone, 2-methoxy-5-(4-methylbenzoyl)phenyl 2-chloroacetate, 4-methylbenzoyl chloride, 2-methoxyphenyl 2-chloroacetate or 2-methoxyphenol in the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile and to a compound which is 4-hydroxy-5-methoxy-2-(4-methylbenzyl)isophthalaldehyde dioxime or 4-hydroxy-5-methoxy-2-(4-methylbenzyl)isophthalaldehyde and use thereof in the preparation of 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile. 4,5-Dihydroxy-2-(4-methylbenzyl)isophthalonitrile is a COMT inhibitor.